---
title: "Aldeyra Therapeutics updates reproxalap NDA data, outlines FDA meeting and AbbVie option"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284917782.md"
description: "Aldeyra Therapeutics has updated its corporate overview regarding reproxalap, revealing standardized efficacy estimates from trials and interpretations of FDA positions. Key points include a Complete Response Letter from the FDA due to insufficient evidence of efficacy, with a Type A meeting scheduled for Q2 2026. The company also outlined an exclusive option with AbbVie involving $100M upfront, milestone payments, and a profit split. Additionally, Aldeyra provided updates on its pipeline, with several trials expected to initiate in 2026 and a cash runway extending into 2028."
datetime: "2026-05-01T15:53:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284917782.md)
  - [en](https://longbridge.com/en/news/284917782.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284917782.md)
---

# Aldeyra Therapeutics updates reproxalap NDA data, outlines FDA meeting and AbbVie option

**Aldeyra Therapeutics released an updated corporate overview disclosing standardized efficacy estimates for reproxalap trials and its interpretations of FDA positions.**

**Key Highlights:**

-   Furnished Corporate Overview (Exhibit 99.1) showing standardized treatment estimates and CIs for primary endpoints of reproxalap trials submitted in the dry eye disease NDA.
-   Summarized FDA positions and Aldeyra’s abbreviated interpretations on primary endpoints; Aldeyra asserts majority of trials support reproxalap efficacy.
-   Noted FDA issued a Complete Response Letter citing insufficient substantial evidence of efficacy; Type A meeting with FDA expected Q2 2026 to discuss the letter.
-   Outlined exclusive AbbVie option: $100M upfront less option fees, $100M approval milestone, $200M additional milestones, 60/40 profit split in U.S., and tiered royalties outside U.S.
-   Provided pipeline and milestones: ADX-2191 Phase 3 and Phase 2/3 initiations expected H1 2026; ADX-248 and ADX-246 IND/planned trials expected in 2026; cash runway noted to fund into 2028 (company guidance).

Original SEC Filing: Aldeyra Therapeutics, Inc. \[ ALDX \] - 8-K - May. 01, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ALDX.US](https://longbridge.com/en/quote/ALDX.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [BeOne Medicines: Recent FDA Approval Rewrites One-Drug Narrative](https://longbridge.com/en/news/287245995.md)
- [Oragenics advances ONP-002 Phase IIa in Australia, $6.1M cash and LOI for CNS device](https://longbridge.com/en/news/286915159.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)
- [How Investors May Respond To Exelixis (EXEL) Merck MRD+ Colorectal Cancer Trial Collaboration](https://longbridge.com/en/news/287252835.md)
- [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md)